IP Library › Granted Patent US 12,391,752
Granted Patent B2
US 12,391,752 · App. 18/168,519 · Granted Aug 19, 2025

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

Inventors: Laurens Kruidenier (San Diego, CA); Mahyar Sabripour (San Diego, CA); Janine Bilsborough (Adelaide, AU); Dermot P. McGovern (Los Angeles, CA); Dalin Li (Los Angeles, CA)
Assignees: PROMETHEUS BIOSCIENCES, INC.; CEDARS-SINAI MEDICAL CENTER
C07K16/241A61P1/00A61P1/04C07K16/2875C12Q1/6883A61K2039/505C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,752
App. No.
18/168,519
Granted
Aug 19, 2025
Kind
B2
Abstract

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Claims (76)

1. A method of enriching a plurality of target nucleic acids in a biological sample from a subject with an inflammatory bowel disease (IBD), the method comprising:

(a) contacting a plurality of synthetic oligonucleotide molecules with the plurality of target nucleic acids, wherein each of the target nucleic acids in the plurality of target nucleic acids is complementary to at least one of the plurality of synthetic oligonucleotide molecules;

(b) hybridizing the plurality target nucleic acids to the at least one of the plurality of the synthetic oligonucleotide molecules;

(c) amplifying the plurality of target nucleic acids hybridized to the at least one of the plurality of synthetic oligonucleotide molecules in (b), thereby producing enriched target nucleic acids; and

(d) detecting the enriched target nucleic acids, wherein the detecting is predictive of a positive therapeutic response to an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression with a positive predictive value (PPV) of at least about 70%.

2. The method of claim 1 , wherein the plurality of target nucleic acid sequences comprise three or more polymorphisms selected from rs56124762, rs1892231, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs16901748, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs1690492, rs420726, rs7759385, rs2548147, rs7278257, rs11221332, and a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

3. The method of claim 2 , wherein the three or more polymorphisms comprise rs6478109, rs16901748, and rs2297437, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

4. The method of claim 2 , wherein the three or more polymorphisms comprise rs6478109, rs2070557, and rs7935393, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

5. The method of claim 2 , wherein the three or more polymorphisms comprise rs6478109, rs7278257, and rs7935393, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

6. The method of claim 2 , wherein the three or more polymorphisms comprise rs6478109, rs9806914, and rs1892231, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

7. The method of claim 2 , wherein the three or more polymorphisms comprise rs6478109, rs7278257, and rs16901748, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

8. The method of claim 7 , wherein the proxy polymorphism for rs7278257 is rs56124762.

9. The method of claim 1 , wherein the detecting is predictive of a positive therapeutic response to the inhibitor of the TL1A activity or expression with a specificity of at least about 80%.

10. The method of claim 1 , wherein the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

11. The method of claim 1 , wherein the plurality of target nucleic acids comprise rs6478109, rs16901748, and rs2297437.

12. The method of claim 1 , wherein the plurality of target nucleic acids comprise rs6478109, rs9806914, and rs1892231.

13. The method of claim 11 , wherein:

(a) the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

i. a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

ii. a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141; and

(b) the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

14. The method of claim 12 , wherein:

(a) the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

i. a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

ii. a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141; and

(b) the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

15. The method of claim 1 , wherein the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

(a) a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

(b) a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141.

16. The method of claim 15 , wherein:

(a) the VH comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 142;

(b) the VL comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 143; or

(c) the VH comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 142, and the VL comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 143.

17. The method of claim 15 , wherein the antibody or antigen binding fragment thereof comprises:

(a) a heavy chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 144;

(b) a light chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 145; or

(c) a heavy chain comprising the amino acid sequence that is at least 90% identical to SEQ ID NO: 144, and a light chain comprising the amino acid sequence that is at least 90% identical to SEQ ID NO: 145.

18. A method of preparing a deoxyribonucleic acid (DNA) fraction useful for analyzing a combination of genotypes predictive of a positive therapeutic response to an inhibitor of tumor necrosis factor-like cytokine 1A (TL1A) activity or expression, the method comprising:

(a) extracting DNA from a sample obtained from a subject with an inflammatory bowel disease (IBD) to obtain DNA fragments;

(b) producing the DNA fraction by:

i. bringing the DNA fragments into contact with a plurality of synthetic oligonucleotides, wherein each of the DNA fragments comprise a target nucleic acid complementary to one or more of the plurality of synthetic oligonucleotides;

ii. hybridizing the target nucleic acid of each of the DNA fragments with the one or more of the plurality of synthetic oligonucleotides; and

iii. amplifying the target nucleic acid of each of the DNA fragments to produce amplified target nucleic acids; and

(c) analyzing the amplified target nucleic acids to detect the combination of genotypes, wherein the combination of genotypes is predictive of the positive therapeutic response to the inhibitor of TL1A activity or expression with a positive predictive value (PPV) of at least about 70%.

19. The method of claim 18 , wherein the target nucleic acids comprise three or more polymorphisms selected from rs56124762, rs1892231, rs6478109, rs2070558, rs2070561, rs11897732, rs6740739, rs17796285, rs7935393, rs12934476, rs12457255, rs2070557, rs4246905, rs10974900, rs12434976, rs16901748, rs2815844, rs889702, rs2409750, rs1541020, rs4942248, rs2297437, rs41309367, rs10733509, rs10750376, rs10932456, rs1326860, rs1528663, rs951279, rs9806914, rs1690492, rs420726, rs7759385, rs2548147, rs7278257, rs11221332, and a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

20. The method of claim 19 , wherein the three or more polymorphisms comprise rs6478109, rs16901748, and rs2297437, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

21. The method of claim 19 , wherein the three or more polymorphisms comprise rs6478109, rs2070557, and rs7935393, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

22. The method of claim 19 , wherein the three or more polymorphisms comprise rs6478109, rs7278257, and rs7935393, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

23. The method of claim 19 , wherein the three or more polymorphisms comprise rs6478109, rs9806914, and rs1892231, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

24. The method of claim 19 , wherein the three or more polymorphisms comprise rs6478109, rs7278257, and rs16901748, or a proxy polymorphism in linkage disequilibrium therewith as determined with an r 2 of at least 0.85.

25. The method of claim 24 , wherein the proxy polymorphism for rs7278257 is rs56124762.

26. The method of claim 18 , wherein the analyzing is predictive of a positive therapeutic response to the inhibitor of TL1A activity or expression with a specificity of at least about 80%.

27. The method of claim 18 , wherein the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

28. The method of claim 18 , wherein the plurality of target nucleic acids comprise rs6478109, rs16901748, and rs2297437.

29. The method of claim 18 , wherein the plurality of target nucleic acids comprise rs6478109, rs9806914, and rs1892231.

30. The method of claim 28 , wherein:

(a) the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

i. a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

ii. a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141; and

(b) the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

31. The method of claim 29 , wherein:

(a) the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

i. a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

ii. a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141; and

(b) the inflammatory bowel disease (IBD) is Crohn's disease (CD) or ulcerative colitis (UC).

32. The method of claim 18 , wherein the inhibitor of TL1A activity or expression comprises an antibody or antigen binding fragment thereof comprising:

(a) a heavy chain variable region (VH) comprising a complementarity determining region (CDR)-H1 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 135; and

(b) a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 141.

33. The method of claim 32 , wherein:

(a) the VH comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 142;

(b) the VL comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 143; or

(c) the VH comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 142, and the VL comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence of SEQ ID NO: 143.

34. The method of claim 32 , wherein the antibody or antigen binding fragment thereof comprises:

(a) a heavy chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 144;

(b) a light chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 145; or

(c) a heavy chain comprising the amino acid sequence that is at least 90% identical to SEQ ID NO: 144, and a light chain comprising the amino acid sequence that is at least 90% identical to SEQ ID NO: 145.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2023
From: BILSBOROUGH, JANINE; MCGOVERN, DERMOT P.; LI, DALIN
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 063250/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2023
From: KRUIDENIER, LAURENS; SABRIPOUR, MAHYAR
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 063250/0544 →
Continuity (5)
Division 17409639 · Aug 23, 2021
Continuation 17118441 · Dec 10, 2020
Continuation PCTUS2020032679 · May 13, 2020
Provisional Application 62847798 · May 14, 2019
Related Publication 20230272061A1 · Aug 31, 2023
References Cited (316)
US 4229447A · Porter · 1980 [cited by applicant]
US 4476116A · Anik · 1984 [cited by applicant]
US 4596795A · Pitha · 1986 [cited by applicant]
US 4755386A · Hsiao et al. · 1988 [cited by applicant]
US 5011692A · Fujioka et al. · 1991 [cited by applicant]
US 5017381A · Maruyama et al. · 1991 [cited by applicant]
US 5116817A · Anik · 1992 [cited by applicant]
US 5229135A · Philippon et al. · 1993 [cited by applicant]
US 5739136A · Ellinwood, Jr. et al. · 1998 [cited by applicant]
US 5739163A · Cain et al. · 1998 [cited by applicant]
US 5837284A · Mehta et al. · 1998 [cited by applicant]
US 5840329A · Bai · 1998 [cited by applicant]
US 5858401A · Bhalani et al. · 1999 [cited by applicant]
US 6391452B1 · Antonsen et al. · 2002 [cited by applicant]
US 6667048B1 · Lambert et al. · 2003 [cited by applicant]
US 6960563B2 · Egbaria et al. · 2005 [cited by applicant]
US 7531310B2 · Feder et al. · 2009 [cited by applicant]
US 7838239B2 · Mitsuhashi et al. · 2010 [cited by applicant]
US 8301232B2 · Albert et al. · 2012 [cited by applicant]
US 8463553B2 · Lois · 2013 [cited by applicant]
US 8766034B2 · Shih et al. · 2014 [cited by applicant]
US 9305137B1 · Targan et al. · 2016 [cited by applicant]
US 9332741B2 · Shih et al. · 2016 [cited by applicant]
US 9580752B2 · Rotter et al. · 2017 [cited by applicant]
US 9732385B2 · Barken et al. · 2017 [cited by applicant]
US 9784748B2 · Wang et al. · 2017 [cited by applicant]
US 9902996B2 · Dubinsky · 2018 [cited by applicant]
US 10086072B2 · Singh et al. · 2018 [cited by applicant]
US 10261098B2 · Bielekova et al. · 2019 [cited by applicant]
US 10273542B2 · Hackney et al. · 2019 [cited by applicant]
US 10316083B2 · Michelsen et al. · 2019 [cited by applicant]
US 10322174B2 · Bilsborough et al. · 2019 [cited by applicant]
US 10338083B2 · Westin et al. · 2019 [cited by applicant]
US 10349888B2 · Muniz · 2019 [cited by applicant]
US 10385398B2 · Hakonarson et al. · 2019 [cited by applicant]
US 10407725B2 · Hakonarson et al. · 2019 [cited by applicant]
US 10458996B1 · Kokkotou · 2019 [cited by applicant]
US 10477354B2 · Patel et al. · 2019 [cited by applicant]
US 10544459B2 · Targan et al. · 2020 [cited by applicant]
US 10571467B2 · Singh et al. · 2020 [cited by applicant]
US 10626180B2 · Mcgovern et al. · 2020 [cited by applicant]
US 10633449B2 · Shih et al. · 2020 [cited by applicant]
US 10635787B2 · Hanusiak et al. · 2020 [cited by applicant]
US 10668185B2 · Watkins et al. · 2020 [cited by applicant]
US 10669587B2 · Hackney et al. · 2020 [cited by applicant]
US 10689439B2 · Watkins et al. · 2020 [cited by applicant]
US 10877049B2 · Bielekova et al. · 2020 [cited by applicant]
US 10961581B2 · Garcia-Blanco et al. · 2021 [cited by applicant]
US 11053251B2 · Higuchi · 2021 [cited by applicant]
US 11111539B2 · Hakonarson et al. · 2021 [cited by applicant]
US 11136386B2 · Kruidenier et al. · 2021 [cited by applicant]
US 11160863B2 · Singh et al. · 2021 [cited by applicant]
US 11180565B2 · McGovern et al. · 2021 [cited by applicant]
US 11186872B2 · Gonsky et al. · 2021 [cited by applicant]
US 11236393B2 · Dubinsky et al. · 2022 [cited by applicant]
US 11261493B2 · Hackney et al. · 2022 [cited by applicant]
US 11266730B2 · Faustman · 2022 [cited by applicant]
US 11268149B2 · Targan et al. · 2022 [cited by applicant]
US 11292848B2 · Watkins et al. · 2022 [cited by applicant]
US 11312768B2 · Michelsen et al. · 2022 [cited by applicant]
US 11434296B2 · Shih et al. · 2022 [cited by applicant]
US 11440954B2 · Watkins et al. · 2022 [cited by applicant]
US 12215147B2 · Kruidenier et al. · 2025 [cited by applicant]
US 20030153063A1 · Feder et al. · 2003 [cited by applicant]
US 20030198640A1 · Yu et al. · 2003 [cited by applicant]
US 20030224400A1 · Barber et al. · 2003 [cited by applicant]
US 20090317388A1 · Burkly et al. · 2009 [cited by applicant]
US 20100136543A1 · Georges et al. · 2010 [cited by applicant]
US 20100190162A1 · Rotter et al. · 2010 [cited by applicant]
US 20100240043A1 · Rotter et al. · 2010 [cited by applicant]
US 20110033486A1 · Abbas et al. · 2011 [cited by applicant]
US 20110160085A1 · Li et al. · 2011 [cited by applicant]
US 20110177502A1 · Hakonarson et al. · 2011 [cited by applicant]
US 20140154275A1 · Abbas et al. · 2014 [cited by applicant]
US 20150132311A1 · Arch et al. · 2015 [cited by applicant]
US 20150301055A1 · Spetzler · 2015 [cited by applicant]
US 20150376707A1 · Targan et al. · 2015 [cited by applicant]
US 20160090629A1 · McGovern · 2016 [cited by applicant]
US 20160215046A1 · Michelsen et al. · 2016 [cited by applicant]
US 20170051351A1 · Hakonarson et al. · 2017 [cited by applicant]
US 20170051352A1 · Hakonarson et al. · 2017 [cited by applicant]
US 20170166967A1 · Rotter et al. · 2017 [cited by applicant]
US 20170185737A1 · Kovacs · 2017 [cited by applicant]
US 20170242043A1 · Bielekova et al. · 2017 [cited by applicant]
US 20180110855A1 · Bilsborough et al. · 2018 [cited by applicant]
US 20180230543A1 · McGovern · 2018 [cited by applicant]
US 20180284010A1 · Scarcelli et al. · 2018 [cited by applicant]
US 20180305459A1 · McGovern et al. · 2018 [cited by applicant]
US 20190070166A1 · Postrel · 2019 [cited by applicant]
US 20190194754A1 · Mcgovern et al. · 2019 [cited by applicant]
US 20190211400A1 · Rotter et al. · 2019 [cited by applicant]
US 20190247498A1 · Bilsborough et al. · 2019 [cited by applicant]
US 20190256913A1 · Hackney et al. · 2019 [cited by applicant]
US 20190265254A1 · Bielekova et al. · 2019 [cited by applicant]
US 20200080152A1 · Hakonarson et al. · 2020 [cited by applicant]
US 20200157203A1 · Watkins et al. · 2020 [cited by applicant]
US 20200255510A1 · Watkins et al. · 2020 [cited by applicant]
US 20200318066A1 · Sharei et al. · 2020 [cited by applicant]
US 20200325538A1 · Hackney et al. · 2020 [cited by applicant]
US 20200362025A1 · Kruidenier et al. · 2020 [cited by applicant]
US 20210001849A1 · Miura · 2021 [cited by applicant]
US 20210038709A1 · Loughhead et al. · 2021 [cited by applicant]
US 20210070871A1 · Watkins et al. · 2021 [cited by applicant]
US 20210093718A1 · Bilsborough et al. · 2021 [cited by applicant]
US 20210122828A1 · Watkins et al. · 2021 [cited by applicant]
US 20210180133A1 · Garcia-Blanco et al. · 2021 [cited by applicant]
US 20210223265A1 · Stappenbeck et al. · 2021 [cited by applicant]
US 20210325387A1 · Shalek et al. · 2021 [cited by applicant]
US 20210371931A1 · McGovern · 2021 [cited by applicant]
US 20210382050A1 · Shea et al. · 2021 [cited by applicant]
US 20220056529A1 · Hakonarson et al. · 2022 [cited by applicant]
US 20220096629A1 · Singh et al. · 2022 [cited by applicant]
US 20220112625A1 · Postrel · 2022 [cited by applicant]
US 20220186314A1 · Hackney et al. · 2022 [cited by applicant]
US 20220193215A1 · Faustman · 2022 [cited by applicant]
US 20220259320A1 · Watkins et al. · 2022 [cited by applicant]
US 20220260565A1 · Underhill et al. · 2022 [cited by applicant]
US 20220291238A1 · Li et al. · 2022 [cited by applicant]
US 20230018729A1 · Kruidenier et al. · 2023 [cited by applicant]
US 20230192835A1 · Watkins et al. · 2023 [cited by applicant]
US 20230272098A1 · Kruidenier et al. · 2023 [cited by applicant]
US 20230381308A1 · Bilsborough et al. · 2023 [cited by applicant]
US 20240209103A1 · Potdar et al. · 2024 [cited by applicant]
EP 2005175B1 · 2011 [cited by applicant]
EP 2257643B1 · 2015 [cited by applicant]
WO WO02053596A2 · 2002 [cited by applicant]
WO WO02053598A2 · 2002 [cited by applicant]
WO WO02059264A2 · 2002 [cited by applicant]
WO WO2007117611A2 · 2007 [cited by applicant]
WO WO2008106451A2 · 2008 [cited by applicant]
WO WO2008107389A1 · 2008 [cited by applicant]
WO WO2009052512A2 · 2009 [cited by applicant]
WO WO2009105590A2 · 2009 [cited by applicant]
WO WO2012064682A1 · 2012 [cited by applicant]
WO WO2012154987A1 · 2012 [cited by applicant]
WO WO2013074676A2 · 2013 [cited by applicant]
WO WO2014106602A1 · 2014 [cited by applicant]
WO WO2014186750A2 · 2014 [cited by applicant]
WO WO2015136446A1 · 2015 [cited by applicant]
WO WO2015148809A1 · 2015 [cited by applicant]
WO WO2016028699A2 · 2016 [cited by applicant]
WO WO2016028699A3 · 2016 [cited by applicant]
WO WO2016028699A8 · 2016 [cited by applicant]
WO WO2017035010A1 · 2017 [cited by applicant]
WO WO2017035017A1 · 2017 [cited by applicant]
WO WO2017049024A1 · 2017 [cited by applicant]
WO WO2017059132A1 · 2017 [cited by applicant]
WO WO2017106383A1 · 2017 [cited by applicant]
WO WO2017189846A1 · 2017 [cited by applicant]
WO WO2018081074A1 · 2018 [cited by applicant]
WO WO2018195328A1 · 2018 [cited by applicant]
WO WO2019018440A1 · 2019 [cited by applicant]
WO WO2019073391A1 · 2019 [cited by applicant]
WO WO2019079647A2 · 2019 [cited by applicant]
WO WO2019178005A2 · 2019 [cited by applicant]
WO WO2019178005A3 · 2019 [cited by applicant]
WO WO2019209942A1 · 2019 [cited by applicant]
WO WO2019209995A2 · 2019 [cited by applicant]
WO WO2019210203A1 · 2019 [cited by applicant]
WO WO2019212899A1 · 2019 [cited by applicant]
WO WO2020010139A1 · 2020 [cited by applicant]
WO WO2020081186A1 · 2020 [cited by applicant]
WO WO2020082090A1 · 2020 [cited by applicant]
WO WO2020112890A1 · 2020 [cited by applicant]
WO WO2020113116A1 · 2020 [cited by applicant]
WO WO2020139748A1 · 2020 [cited by applicant]
WO WO2020163713A1 · 2020 [cited by applicant]
WO WO2020163715A1 · 2020 [cited by applicant]
WO WO2020176789A1 · 2020 [cited by applicant]
WO WO2020232125A1 · 2020 [cited by applicant]
WO WO2020242976A1 · 2020 [cited by applicant]
WO WO2021016090A1 · 2021 [cited by applicant]
WO WO2021081365A1 · 2021 [cited by applicant]
WO WO2021108694A1 · 2021 [cited by applicant]
WO WO2021247548A1 · 2021 [cited by applicant]
WO WO2021247770A1 · 2021 [cited by applicant]
WO WO2021260577A2 · 2021 [cited by applicant]
WO WO2022087313A1 · 2022 [cited by applicant]
WO WO2022091085A1 · 2022 [cited by applicant]
WO WO2022103961A1 · 2022 [cited by applicant]
WO WO2022119842A1 · 2022 [cited by applicant]
WO WO2022140283A1 · 2022 [cited by applicant]
WO WO2022178158A1 · 2022 [cited by applicant]
WO WO2022178159A1 · 2022 [cited by applicant]
WO WO2022187196A1 · 2022 [cited by applicant]
WO WO2022232253A1 · 2022 [cited by applicant]
Al-Lazikani, Bissan, et al., Standard Conformations for the Canonical Structures of Immunoglobulins. Journal of Molecular Biology 273(4):927-948 (1997). [cited by applicant]
Andiappan, et al. Evaluating the transferability of Hapmap SNPs to a Singapore Chinese population. BMC Genetics, 11.36 (2010). [cited by applicant]
Bauer et al., A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis. Gene, 37:73-81, 1985. [cited by applicant]
Bhattacharya et al.: Impact of genetic variation on three dimensional structure and function of proteins. PLoS ONE. 12(3):e0171355 (2017). [cited by applicant]
Bork: Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10):425-427 (1996). [cited by applicant]
Bork: Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Res. 10:398-400 (2000). [cited by applicant]
Brennan et al. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81-83, 1985. [cited by applicant]
Brenner: Errors in genome annotation. Trends in Genetics. 15:132-133 (1999). [cited by applicant]
Brorson et al.: Mutational Analysis of Avidity and Fine Specifictiy of Anti-Levan Antibodies. J. Immunol. 163:6694-6701 (1999). [cited by applicant]
Bruggemann et al.: Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies. J. Exp. Med. 166:1351-1361 (1987). [cited by applicant]
Casset et al.: A peptide mimetic of an anti-CD4 monoclonal antibody by rationale design. Biochem Biophys Res Comm. 307:198-205 (2003). [cited by applicant]
Chen et al.: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 293:865-881 (1999). [cited by applicant]
ClinicalTrials.gov website: A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis (ARTEMIS-UC) ClinicalTrials.gov https://classic.clinicaltrials.gov/ct2/show/NCT… [cited by applicant]
ClinicalTrials.gov website:A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease (APOLLO-CD) ClinicalTrials.gov https://classic.clinicaltrials.gov/ct2/s… [cited by applicant]
Clynes et al. Fc receptors are required in passive and active immunity to melanoma. PNAS USA 95(2):652-656 (1998). [cited by applicant]
Colman: Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunol. 145:33-36 (1994). [cited by applicant]
Co-pending U.S. Appl. No. 18/546,947, filed Aug. 17, 2023. [cited by applicant]
Co-pending U.S. Appl. No. 18/557,551, filed Oct. 26, 2023. [cited by applicant]
Craik, Charles. Use of oligonucleotides for site-specific mutagenesis. BioTechniques 1985 :12-19, 1985. [cited by applicant]
DePascalis et al.: Grafting and “abbreviated” complementarity-determining regions containing specificity-determining residues essential for Ligand contact to engineer a less immunogenic humanized monoclonal antibody. J.… [cited by applicant]
Doerks et al.: Protein annotation: detective work for function prediction. Trends in Genetics. 14:248-250 (1998). [cited by applicant]
Fenton et al.: Rheostat positions: a new classification of protein positions relevant to pharmacogenomics. Medicinal Chem Res. 29:1133-1146 (2020). [cited by applicant]
Gazzano-Santoro et al.: A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 202(2):163-171 (1997). [cited by applicant]
Guo et al.: Protein tolerance to random amino acid change. Proc Natl Acad Sci. USA 101(25):9205-9210 (2004). [cited by applicant]
Holm et al.: Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol 44:1075-1084 (2007). [cited by applicant]
Honegger et al.: Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool. Journal of Molecular Biology 309(3):657-670 (2001). [cited by applicant]
https://www.genecards.org/cgi-bin/carddisp.pl?gene=JAK2 (viewed on the internet Aug. 11, 2023). [cited by applicant]
https://www.genecards.org/cgi-bin/carddisp.pl?gene=RSPO1 (viewed on the internet Aug. 11, 2023). [cited by applicant]
Jang et al.: The structural basis for DNA binding by an anti-DNA autobody. Mol Immunol 35:1207-1217 (1998). [cited by applicant]
Kabat et al.: Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health 1:647-669 (1991). [cited by applicant]
Karlin and Altschul: Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990). [cited by applicant]
Karlin et al.: Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences. Proceedings of the National Academy of Sciences of the United States of America 90(12):5873-5877 (1993). [cited by applicant]
Karlin et al.: Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proceedings of the National Academy of Sciences of the United States of America 87(6):22… [cited by applicant]
Lefranc et al.: IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains And Ig Superfamily V-like Domains. Developmental & Comparative Immunology 27(1):55-77 (2003). [cited by applicant]
Maccallum et al.: Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Maniatis et al., Isolation of high-molecular-weight, eukaryotic DNA from cells grown in tissue culture. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., pp. 280-281 (1982). [cited by applicant]
Michelsen et al., IBD-Associated TL 1A Gene (TNFSF15) Haplotypes Determine Increased Expression of TL 1A Protein. PLoS ONE. 4:e4719 (2009). [cited by applicant]
Morimoto et al. Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW. J Biochem Biop… [cited by applicant]
Takedatsu et al.: TL1A (TNFSF15) Regulates the Development of Chronic Colitis By Modulating both T helper (TH) 1 and TH17 Activation; Gastroenterology; HHS Public Access; 135(2): 552-567 (2008). [cited by applicant]
Patel, et al. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J Immunol Methods. Jul. 17, 1995;184(1):29-38. [cited by applicant]
Parl: Fundamental Immunology. 3rd Edition. Raven Press. New York. Chapter 8. pp. 292-295 (1993). [cited by applicant]
PCT Patent Application No. PCT/US2024/016224 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016257 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016264 filed Feb. 16, 2024. [cited by applicant]
PCT Patent Application No. PCT/US2024/016280 filed Feb. 16, 2024. [cited by applicant]
PCT/US2021/058979 International Preliminary Report on Patentability dated May 25, 2023. [cited by applicant]
PCT/US2021/058979 International Search Report and Written Opinion dated Apr. 11, 2022. [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 1 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 8, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Amendment No. 2 to Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (245 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Feb. 28, 2023 (129 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10K Annual Report as filed with the Securities and Exchange Commission on Mar. 9, 2022 (125 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form 10-K/A Annual Report (Amendment No. 1) as filed with the Securities and Exchange Commission on Apr. 28, 2023 (42 pages). [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Mar. 11, 2021 (4 pages). [cited by applicant]
Prometheus Biosciences: Transcriptional and Microbial Biomarkers of Response to Anti-TL1A Therapy in Ulcerative Colitis: The Phase 2a TUSCANY Study. The European Crohn's and Colitis Organization conference from Feb. 12-… [cited by applicant]
Sela-Culang et al.: The structural basis of antibody-antigen recognition. Front Immunol. 4(302):1-13 (2013). [cited by applicant]
Skolnick et al.: From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-39 (2000). [cited by applicant]
Smith et al.: The challenges of genome sequence annotation or “the devil is in the details”. Nature Biotechnol. 15:1222-1223 (1997). [cited by applicant]
Sotos, et al. The Transitivity Misconception of Pearson's Correlation Coefficient. Statistics Education Research Journal. 8(2):33-55 (2009). [cited by applicant]
Stahle, et al. Multivariate data analysis and experimental design in biomedical research. Prog. Med. Chem., vol. 25, Chapter 6, 291-338, 1988. [cited by applicant]
Tokuriki et al.: Stability effects of mutations and protein evolvability. Curr Opin Structural Biol. 19:596-604 (2009). [cited by applicant]
U.S. Appl. No. 17/682,922 Office Action dated Dec. 14, 2023. [cited by applicant]
U.S. Appl. No. 18/546,938, filed Feb. 27, 2024. [cited by applicant]
U.S. Appl. No. 18/546,947, filed Aug. 27, 2023. [cited by applicant]
U.S. Appl. No. 15/931,452 Office Action dated Feb. 15, 2024. [cited by applicant]
U.S. Appl. No. 17/931,049 Office Action dated Mar. 12, 2024. [cited by applicant]
Vajdos, Felix F, et al., Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis. Journal of Molecular Biology 320(2):415-428 (2002). [cited by applicant]
Vasudevan et al.: A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cells Mol Diseases. 32:176-181 (2004). [cited by applicant]
Walder et al. Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system. Gene 42:133-139, 1986. [cited by applicant]
Wallach et al.: Chapter 29: Insights into TL1A and IBD Pathogenesis, Advances in TNF Family Research—Conf—12th Biennial International Tumor Necrosis Factor Conference; [Advances in Experimental Medicine and Biology; ISS… [cited by applicant]
Whitelegg et al.: WAM: An Improved Algorithm for Modelling Antibodies on the WEB. Protein Engineering 13(12):819-824 (2000). [cited by applicant]
Wilkinson, et al. Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. J Immunol Methods. Dec. 1, 2001;258(1-2):183-91. [cited by applicant]
Wisecarver et al.: A method for determination of antibody-dependent cellular cytotoxicity (ADCC) of human peripheral mononuclear cells. J Immunol Methods. May 23, 1985;79(2):277-282. [cited by applicant]
Wold, et al. PLS-regression: a basic tool of chemometrics. Chemom. Intell. Lab Syst. 2001, 58: 109-130. [cited by applicant]
Wu et al.: Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. 294:151-162 (1999). [cited by applicant]
Zhang et al.: Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1):42-52 (2015). [cited by applicant]
Altschul et al.: Basic local alignment search tool, J mol. Boil, 1990, 215:403-410. [cited by applicant]
Altschul et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402 (1997). [cited by applicant]
Barrett et al.: Constitutive TL1A Expression under Colitogenic Condition Modulates the Severity and Location of Gut Mucosal Inflammation and Induces Fibrostenosis, American Journal of Pathology, 180(2):636-649 (2012). [cited by applicant]
Behravan et al.: Machine learning identifies interacting genetic variants contributing to breast cancer risk: A case study in Finnish cases and controls. Sci Rep. 8:13149 (2018). [cited by applicant]
Breuer et al.: Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics. International Journal of Bipolar Disorders. 6(24):10 pages (2018). [cited by applicant]
Chatterjee et al.: Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nature Reviews, Genetics. pp. 1-15 (2016). [cited by applicant]
Choi et al.: A guide to performing Polygenic Risk Score analyses. bioRxiv. 22 pages (2018) http://dx.doi.org/10.1101/416545. [cited by applicant]
DbSNP Short Genetic Variations Submitted SNP(ss). Details: ss112518351 Mar. 29, 2020 [online]. Retrieved Oct. 5, 2020 URL:https://www.ncbi.nim.nih.gov/projects/SNP/snp_ss.cgi?subsnp_id=ss112518351. [cited by applicant]
DbSNP Short Genetic Variations Submitted SNP(ss). Details: ss226749241. Jul. 20, 2011 [online] Retrieved Oct. 5, 2020. URL:https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?subsnp_id=ss226749241dbSNP Short Genetic Va… [cited by applicant]
De Lange et al.: Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet.: 49(2):256-261 (2017). [cited by applicant]
Ellinghaus et al.: Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat. Genet. 48(5):510-518 (2016). [cited by applicant]
Golumbeanu et al.: Clustering time series gene expression data with TMixClusT. Department of Biosystems Science and Engineering, ETH Zuerich, Switzerland. 16 pages (2018). [cited by applicant]
Herro et al.: TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. J Immunol. 205(9):2414-2422 (2020) doi: 10.4049/jimmunol.2000665. Epub Sep. 21, 2020. [cited by applicant]
Huang et al.: Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 547(7662):173-178 (2017). [cited by applicant]
Jostins et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature; 491/7422:119-124 (2012). [cited by applicant]
Landers et al.: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens; Gastroenterology; 123:689-699 (2002). [cited by applicant]
Li et al.: Late-Onset Crohn's Disease is a Subgroup Distinct in Genetic and Behavioral Risk Factors with UC-Like Characteristics. Inflamm Bowel Dis. 12;24(11):2413-2422 (2018). [cited by applicant]
Liu et al.: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations; Nature Genetics; 47, 979-986 (2015). [cited by applicant]
Machiela et al.: LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 31(21):3555-3557 (2015). [cited by applicant]
Medrano et al. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Human Immunology 75(1):71-75 (2014). [cited by applicant]
NCBI dbSNP Short Genetic Variations Reference SNP (rs) Report for rs1892231. Jan. 25, 2009 submission. [online] Retrieved Oct. 5, 2020. URL:https://www.ncbi.nlm.nih.gov/snp/rs1892231#submissions. [cited by applicant]
NCBI dbSNP Short Genetic Variations Reference SNP (rs) Report for rs56124762. Jan. 25, 2009 submission [online] Retrieved Oct. 5, 2020 URL:https://www.ncbi.nlm.nih.gov/snp/rs56124762#submissions. [cited by applicant]
Ollech: Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up. Abstracts of t… [cited by applicant]
PCT/US2020/032679 International Search Report and Written Opinion dated Oct. 22, 2020. [cited by applicant]
PCT/US2020/032679 Invitation to Pay Additional Fees dated Aug. 24, 2020. [cited by applicant]
Pierik et al. Tumour Necrosis Factor-a Receptor 1 and 2 Polymorphisms in Inflammatory Bowel Disease and their Association with Response to Infliximab. Alimentary Pharmacology & Therapeutics 20(3):303-310 (2004). [cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Feb. 19, 2021 (246 pages). [cited by applicant]
Remington: The Science and Practice of Pharmacy. 21st Edition, Lippincott Williams & Wilkins (2005). [cited by applicant]
Safety, Efficacy, and Tolerability Study of PF-0648064 in Subjects with Moderate to Sever Ulcerative Colitis. Phase II for PF-06480605 (Pfizer, https://clinicaltrials.gov/ct2/show/NCT02840721 ). [cited by applicant]
Saxon et al.: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin. Immunol. 86:202-210 (1990). [cited by applicant]
Shih et al.: Reversal of Murine Colitis and Fibrosis by Neutralizing TL1A Antibody: Potential Novel Therapy to Alter Natural History of Crohn's Disease. Gastroenterology 142(5): s84 (2012). [cited by applicant]
Singh et al. Encyclopedia of Pharmaceutical Technology 2nd Ed. pp. 754-757 (2002). [cited by applicant]
Torkamani et al.: The personal and clinical utility of polygenic risk scores. Nature Reviews, Genetics. 10 pages (2018). [cited by applicant]
U.S. Appl. No. 15/931,452 Restriction Requirement dated Oct. 3, 2022. [cited by applicant]
U.S. Appl. No. 17/118,441 Final Office Action dated Jun. 25, 2021. [cited by applicant]
U.S. Appl. No. 17/118,441 Office Action dated Mar. 10, 2021. [cited by applicant]
U.S. Appl. No. 17/118,441 Restriction Requirement dated Feb. 8, 2021. [cited by applicant]
Yamazaki et al.: Single nucleotide polymorphisms in TNFSF15 confers susceptibility to Crohn's disease. Hum Mol Genet 14:3499-3506 (2005). [cited by applicant]
Yu et al.: Downregulation of VEGF and upregulation of TL1A expression induce HUVEC apoptosis in response to high glucose stimuli. Mol Med Rep. 13(4):3265-72 (2016) doi: 10.3892/mmr.2016.4924. Epub Feb. 22, 2016. [cited by applicant]
Baskaran et al., Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with ulcerative colitis and Crohn's disease in an Indian population. PLoS One 9(12):e114665 (2014). [cited by applicant]
Brennan, Maureen et al. Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments. Science 229(4708):81-83 (1985). [cited by applicant]
U.S. Pat. No. 10,322,174 B2 Listing of Claims (p. 46) issued on Jun. 18, 2019. [cited by applicant]
U.S. Pat. No. 10,689,439 B2 Listing of Claims (pp. 192-193) issued on Jun. 23, 2020. [cited by applicant]
U.S. Pat. No. 11,136,386 B2 Listing of Claims (pp. 158-159) issued on Oct. 5, 2021. [cited by applicant]
U.S. Pat. No. 11,292,848 B2 Listing of Claims (pp. 346-347) issued on Apr. 5, 2022. [cited by applicant]
U.S. Pat. No. 11,440,954 B2 Listing of Claims (pp. 191-192) issued on Sep. 13, 2022. [cited by applicant]
U.S. Pat. No. 11,999,789 B2 Listing of Claims (p. 348) issued on Jun. 4, 2024. [cited by applicant]
U.S. Appl. No. 15/931,452 Listing of Claims as of Aug. 13, 2024. [cited by applicant]
U.S. Appl. No. 17/409,639 Listing of Claims as of Sep. 30, 2024. [cited by applicant]
U.S. Appl. No. 18/191,712 Listing of Claims as of Oct. 29, 2024. [cited by applicant]
U.S. Appl. No. 18/316,811 Listing of Claims as of Aug. 11, 2023. [cited by applicant]
U.S. Appl. No. 18/546,938 Listing of Claims as of Sep. 11, 2024. [cited by applicant]
U.S. Appl. No. 18/546,947 Listing of Claims as of Mar. 25, 2024. [cited by applicant]
U.S. Appl. No. 18/645,261 Listing of Claims as of Apr. 24, 2024. [cited by applicant]
U.S. Appl. No. 18/649,944 Listing of Claims as of Jul. 29, 2024. [cited by applicant]